Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 188,888 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $12.54, for a total value of $2,368,655.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Thursday, April 4th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36.
• On Wednesday, March 20th, Andrew Dudum sold 50,361 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.34, for a total transaction of $822,898.74.
• On Tuesday, February 13th, Andrew Dudum sold 97,208 shares of Hims & Hers Health stock. The stock was sold at an average price of $9.58, for a total value of $931,252.64.

Hims & Hers Health Stock Down 8.1 %

Shares of HIMS opened at $11.25 on Friday. Hims & Hers Health, Inc. has a one year low of $5.65 and a one year high of $17.16. The business has a fifty day moving average of $13.97 and a 200 day moving average of $10.22.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.03. The firm had revenue of $246.60 million for the quarter, compared to analysts’ expectations of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business’s quarterly revenue was up 47.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.05) EPS. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.11 EPS for the current year.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Jefferies Financial Group reiterated a “hold” rating and set a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. SVB Leerink began coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 price objective on the stock. Guggenheim upped their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Canaccord Genuity Group began coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target for the company. Finally, Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.85.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently bought and sold shares of HIMS. Belpointe Asset Management LLC boosted its position in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after purchasing an additional 1,205 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Hims & Hers Health by 5.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after buying an additional 1,561 shares during the period. Pathstone Family Office LLC increased its stake in Hims & Hers Health by 2.8% in the 3rd quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock worth $414,000 after buying an additional 1,824 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Hims & Hers Health by 17.9% during the first quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock valued at $258,000 after acquiring an additional 2,525 shares during the period. Finally, Baldwin Brothers LLC MA lifted its position in shares of Hims & Hers Health by 17.0% in the fourth quarter. Baldwin Brothers LLC MA now owns 22,128 shares of the company’s stock valued at $197,000 after acquiring an additional 3,215 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.